Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years
August 7, 2020
-
BUSINESS GSK, KM Biologics in Adjuvant Tech Transfer Talks for COVID-19 Vaccines
August 7, 2020
-
BUSINESS MSD Japan Chief Wants Talks with Govt, Re-Pricing Rules Revisited to Help Innovation Thrive
August 6, 2020
-
BUSINESS Celltrion Poised to Roll Out 20 Biosimilars in Japan over Next 10 Years
August 5, 2020
-
BUSINESS Povidone-Iodine Gargle Meds Fly Off Pharmacy Shelves after Osaka COVID-19 Data
August 5, 2020
-
BUSINESS Daiichi Sankyo to Curb Shipments for Herceptin Biosimilar on Surging Demand
August 4, 2020
-
BUSINESS BMS Japan to Integrate Celgene Next Year, HQ Relocation Planned in H1 2022: Chief
August 3, 2020
-
REGULATORY Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
-
BUSINESS Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
-
BUSINESS Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
-
COMMENTARY With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
-
BUSINESS Pfizer Japan Has Different Interpretation on Lyrica Patent Ruling
July 29, 2020
-
BUSINESS Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid
July 28, 2020
-
BUSINESS Nihon Chouzai Launches Drug Information Service with Standard Formulary Including Few New Meds
July 27, 2020
-
BUSINESS 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
-
BUSINESS AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
-
BUSINESS National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
-
REGULATORY 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
-
REGULATORY Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
-
BUSINESS Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…